Announcements
Sidley Represents Atia Vision Inc. in Series E Financing
April 13, 2023
Sidley represented Atia Vision Inc. in its Series E financing led by Cormorant Asset Management with participation by The Capital Partnership, PA MedTech VC Fund, AMED Ventures, and Shifamed Angel investors. Atia Vision Inc., a medical device company, develops modular presbyopia-correcting intraocular lenses to address needs in the intraocular lens replacement market.
The Sidley team was led by Emerging Companies and Venture Capital partner Frank Rahmani (Palo Alto) with the help of managing associate Jake Funk (Palo Alto), senior managing associate Nick DeAngelis (Dallas), and associate Madison Ferraro (Palo Alto). The team also included Food, Drug and Medical Device partner Torrey Cope (Washington, D.C.) and counsel Olivier Goarnisson (Geneva); Securities Enforcement and Regulatory counsel Benjamin L. Nager (New York); Capital Markets partner Daniel A. O'Shea (New York); and Investment Funds staff attorney Shelley Azizi (Los Angeles).
The Sidley team was led by Emerging Companies and Venture Capital partner Frank Rahmani (Palo Alto) with the help of managing associate Jake Funk (Palo Alto), senior managing associate Nick DeAngelis (Dallas), and associate Madison Ferraro (Palo Alto). The team also included Food, Drug and Medical Device partner Torrey Cope (Washington, D.C.) and counsel Olivier Goarnisson (Geneva); Securities Enforcement and Regulatory counsel Benjamin L. Nager (New York); Capital Markets partner Daniel A. O'Shea (New York); and Investment Funds staff attorney Shelley Azizi (Los Angeles).
Contacts
Offices
Capabilities
Suggested News & Insights
Sidley Secures Plan Confirmation in Prospect Medical Holdings' US$2.3 Billion Chapter 11 CaseDecember 17, 2025BIOSECURE Act Included in the FY2026 National Defense Authorization ActDecember 12, 2025U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025What the U.S.–UK Drug Pricing Agreement Reveals About How MFN Drug Policy Could Impact the UK and EUDecember 10, 2025Sidley Represents Lumexa Imaging in US$462.5 Million Initial Public OfferingDecember 10, 2025First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical LabsDecember 8, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory





